Governor Phil Murphy signed legislation tightening New Jersey gun laws; the FDA temporarily suspended the ban on Juul sales; researchers found a cancer drug reduced risk of death among people hospitalized with COVID-19 by half.
New Jersey Governor Phil Murphy signed legislation Tuesday that would make it harder for individuals to obtain a handgun license and purchase high-capacity rifles in the state, The New York Times reported. The new legislation requires individuals to receive training to get a gun license and register firearms purchased out of state, and outlaws .50-caliber weapons. This news follows the Supreme Court’s decision to overturn a New York state gun law, and multiple shootings over Independence Day weekend.
The FDA temporarily suspended its ban on Juul sales, the agency announced Tuesday, clarifying this does not entirely rescind the ban. As reported by The Hill, the FDA found scientific issues unique to Juul’s application that require further review. During this time, Juul is also permitted to market its products in the United States. This announcement was made 2 weeks after the FDA ordered Juul to pull its e-cigarettes from the US market.
Experimental drug sabizabulin was initially developed for cancer treatment, but has been found to reduce the risk of death among people hospitalized with COVID-19 by half, The New York Times reported. According to a study published in The New England Journal of Medicine, the drug was more effective at reducing death compared with other drugs, and works by blocking cells from building microtubules. Because the study only included 134 patients, experts have expressed caution in interpreting the results, and encourage more, larger studies.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Solving the Transition Conundrum as More Children With Muscular Dystrophy Live to Adulthood
March 17th 2025Learning from examples like congenital heart disease and cystic fibrosis can help health systems and clinicians prepare to care for an influx of patients with neuromuscular diseases as they reach adulthood thanks to transformative therapy advances.
Read More
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More